I'm LongbridgeAI, I can summarize articles.Colin Hill, Chief Commercial Officer of LGC Diagnostics and Genomics, highlighted AI and genomics as key drivers reshaping diagnostics. He emphasized that wider adoption depends on clinically meaningful results, improved patient outcomes, and health-economic benefits. Near-term impacts include AI-driven clinical decision support, faster R&D, and large dataset analysis. LGC focuses on standards and controls to ensure assay reliability.
- LGC Diagnostics and Genomics Chief Commercial Officer Colin Hill flagged AI and genomics as key forces reshaping diagnostics, with quality central to adoption. * Hill highlighted minimal residual disease testing in oncology as a potential step-change in monitoring, likening it to viral load testing in HIV. * He said wider uptake of new platforms hinges on clinically meaningful results, improved patient outcomes, decision support for clinicians, health-economic benefit. * Hill pointed to AI-driven clinical decision support, faster diagnostic R&D, analysis of large diagnostic datasets as near-term impact areas. * He positioned LGC’s focus on standards, controls, reference materials, critical raw materials as underpinning assay reliability and supply continuity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LGC Limited published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here